Previous 10 | Next 10 |
home / stock / lxxgf / lxxgf news
September 7-9, WVC 93 rd Annual Conference, Las Vegas, NV September 12-14, International Veterinary Emergency and Critical Care, Nashville, TN September 23-26, Southwest Veterinary Symposium, San Antonio, TX BEVERLY, Mass., Sept. 03, 2021 (GLOBE...
BEVERLY, MA / ACCESSWIRE / August 17, 2021 / LexaGene Holdings, Inc. , (OTCQB:LXXGF) (TSXV:LXG) a molecular diagnostics company developing automated rapid polymerase chain reaction (PCR) testing solutions for veterinary diagnostics and biopharmaceutical manufacturing, today announced tha...
LOS ANGELES, CA / ACCESSWIRE / August 16, 2021 / The SNN Network Summer Virtual Event will take place on August 17-19, 2021, where 60 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience. The SNN Network Summer Virt...
First point-of-need, PCR system capable of using conventional probe-based chemistry or inexpensive, rapidly available SYBR Green chemistry BEVERLY, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc. , ( OTCQB: LXXGF ; TSX-V: LXG ) a molecular diagnos...
Mycoplasmas are thought to contaminate 15-80% of cell cultures worldwide MiQLab rapidly detected 100% of the tested mycoplasma samples within two hours, with no false positives MiQLab can be used inside biopharmaceutical manufacturers to rapidly validate their products as bein...
BEVERLY, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc. , ( OTCQB: LXXGF ; TSX-V: LXG ) (the “ Company ”), a molecular diagnostics company that develops a fully automated rapid pathogen detection system, today announced its strategic rela...
New panel offers extensive improvements for pathogen identification and drug resistance gene testing Increases targeted pathogens from 7 to 10 (140% increase) Increases targeted drug resistance genes from 13 to 35 (270% increase) Two-hour test for 45 ...
LexaGene Holdings (LXXGF) announces that it continues to systematically advance the MiQLab System to meet the FDA criteria for Emergency Use Authorization ((EUA)).The MiQLab System is a first of its kind, point of care diagnostic testing technology. The FDA EUA process requires novel diagnost...
BEVERLY, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc. , ( OTCQB: LXXGF ; TSX-V: LXG ) (the “ Company ”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced it continues to sys...
LexaGene Holdings Inc. (LXXGF): Q4 GAAP EPS of -$0.10.Revenue of $0.06MShares -2.51%.Press Release For further details see: LexaGene Holdings Inc. reports Q4 results
News, Short Squeeze, Breakout and More Instantly...
BEVERLY, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), announces that it has ceased operations, laid off its staff, and, together with its direct subsidiary LexaGene, Inc., and its indir...
BEVERLY, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc. , ( OTCQB: LXXGF ; TSX-V: LXG ) (“ LexaGene ” or the “ Company ”), a molecular diagnostics company that has commercialized the MiQLab™ System for automated mul...
BEVERLY, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc. , ( OTCQB: LXXGF ; TSX-V: LXG ) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab™ System for automate...